Synapse - David Straus

Search Within

David J Straus

Results (356)

Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine for early‐stage classical Hodgkin Lymphoma: Updated results from an ongoing phase 2 study (SGN35‐027 Part C)

Meeting Abstract

Abramson, J. S.; Straus, D.; Bartlett, N.; Burke, J. M.; Lynch, R. C.; Domingo‐Domenech, E.; Hess, B.; Schuster, S.; Linhares, Y.; Ramchandren, R.; more...
Hematological Oncology (2023)

Fulltext@MSK | Save

Phase 2 trial of nivolumab plus adriamycin, vinblastine, dacarbazine (N‐AVD) as frontline therapy in older adults with Hodgkin lymphoma

Meeting Abstract

Torka, P.; Feldman, T.; Savage, K.; Ganesan, N.; Hancock, H.; Davey, T.; Perez, L.; Santarosa, A.; Subzwari, S.; Capadona, C.; more...
Hematological Oncology (2023)

Fulltext@MSK | Save

Outcomes of patients with positive interim positron emission tomography (PET) continuing ABVD in the clinical setting

Journal Article

Zheng, S.; Gupta, K.; Goyal, P.; Nakajima, R.; Michaud, L.; Batlevi, C. L.; Hamlin, P. A.; Horwitz, S.; Kumar, A.; Matasar, M. J.; more...
Cancers (2023)

Fulltext@MSK | Save

Molecularly targeted epigenetic therapy with mocetinostat in relapsed and refractory non-Hodgkin lymphoma with CREBBP or EP300 mutations: An open label phase II study

Research Letter

Qualls, D.; Noy, A.; Straus, D.; Matasar, M.; Moskowitz, C.; Seshan, V.; Dogan, A.; Salles, G.; Younes, A.; Zelenetz, A. D.; more...
Leukemia and Lymphoma (2023)

Fulltext@MSK | Save

First-line brentuximab vedotin plus chemotherapy improves overall survival in patients with stage III/IV classical Hodgkin Lymphoma: An updated analysis of ECHELON-1

Meeting Abstract

Straus, D.; Radford, J.; Connors, J.; Kim, W. S.; Gallamini, A.; Ramchandren, R.; Friedberg, J.; Advani, R.; Hutchings, M.; Evens, A.; more...
Clinical Lymphoma, Myeloma and Leukemia (2022)

Fulltext@MSK | Save

Characterization of a large cohort of patients with nodal marginal zone lymphoma shows prolonged survival, time-to-treatment, and time-to-transformation

Meeting Abstract

Stuver, R.; Drill, E.; Qualls, D.; Okwali, M.; Batlevi, C. L.; Caron, P. C.; Epstein-Peterson, Z. D.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; more...
Blood (2022)

Fulltext@MSK | Save

Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine (AN+AD) for early stage classic Hodgkin lymphoma: Interim efficacy and safety results from the single-arm phase 2 study (SGN35-027 Part C)

Meeting Abstract

Lee, H. J.; Abramson, J. S.; Bartlett, N. L.; Burke, J. M.; Lynch, R. C.; Eva, D. D.; Hess, B. T.; Schuster, S. R.; Linhares, Y.; Ramchandren, R.; more...
Blood (2022)

Fulltext@MSK | Save

Molecular profiling across lymphoma subtypes using MSK-impact next generation sequencing

Meeting Abstract

Batlevi, C. L.; Drill, E.; Okwali, M.; Ptashkin, R.; Caron, P. C.; Epstein-Peterson, Z. D.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; more...
Blood (2022)

Fulltext@MSK | Save

Immune signature of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma

Meeting Abstract

Wills, B.; Ganesan, N.; Shah, G. L.; Wong, P.; Argyropoulos, K. V.; Sen, F.; Dogan, A.; Straus, D. J.; Noy, A.; Kumar, A.; more...
Blood (2022)

Fulltext@MSK | Save

Brentuximab vedotin combined with chemotherapy in newly diagnosed, early-stage, unfavorable-risk Hodgkin lymphoma: Extended follow-up with evaluation of baseline metabolic tumor volume and PET2

Meeting Abstract

Stuver, R.; Michaud, L.; Casulo, C.; Advani, R. H.; Budde, E. L.; Barr, P. M.; Batlevi, C. L.; Caron, P. C.; Constine, L. S.; Dandapani, S.; more...
Blood (2022)

Fulltext@MSK | Save